focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.30
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (1.379%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.30
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Correction to the Form of Proxy

15 Dec 2009 15:12

RNS Number : 1597E
Phytopharm PLC
15 December 2009
 

Correction to the Form of Proxy for Holders of Ordinary Shares, Form of Direction - Share Incentive Plan 2007 and Form of Direction to Exercise Voting Rights - General Meeting, each dated 3 December 2009

Phytopharm plc (the "Company")

In the summaries of the resolutions to be voted on at the general meeting of the Company at 11.00am on 29 December 2009 at the offices of KBC Peel Hunt Ltd, 111 Old Broad Street, London EC2N 1PH, it has been noted that in the Form of Proxy for Holders of Ordinary Shares, Form of Direction - Share Incentive Plan 2007 and Form of Direction to Exercise Voting Rights - General Meeting dated 3 December 2009 (the "Forms"), the summary of resolution 2 refers to shares being issued to an aggregate nominal value of £25,212,904.20 rather than £2,521,290.42; and the summary of resolution 4 refers to a subscription price of £0.01 rather than £0.10.  All other details in the Forms and all details in the notice of general meeting remain unchanged. 

The full text of each of these amended resolution summaries is set out below: "2.  To authorise the Directors for the purposes of section 551 of the Act to exercise all the powers of the Company to allot and grant rights to subscribe for or to convert securities into shares of the Company up to an aggregate nominal amount of £2,521,290.42 pursuant to or in connection with the Placing and Open Offer." "4. To approve the issue of Ordinary Shares pursuant to the Placing and Open Offer at a subscription price of £0.10 each (representing a discount of approximately 33.3 per cent. to the closing middle market price for an Ordinary Share for the business day immediately preceding the date on which the Company announced such price)."

For further information contact:

Phytopharm plc

Tel: +44 (0)1480 437 697

Sandy Morrison (Acting CEO)

Keith Thomson (Interim COO)

Alistair Taylor (Non-executive Chairman)

KBC Peel Hunt Ltd (Sponsor, Broker & Underwriter)

Tel: +44 (0)20 7418 8900

Capel Irwin / Matt Goode (Corporate Finance)

Marianne Woods / Dan Webster (Corporate Broking)

Notes:

Phytopharm is listed on the Official List of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com.

KBC Peel Hunt Ltd, which is regulated by the FSA, is acting as Sponsor, Broker and Underwriter for the Company and is not acting for any other person and will not be responsible to any other person for providing the protections afforded to clients of KBC Peel Hunt Ltd or for providing advice in relation to the Placing and Open Offer, Admission or any other arrangements referred to herein.

This announcement has been issued by, and is the sole responsibility of, Phytopharm. Apart from the responsibilities and liabilities, if any, which may be imposed by FSMA, KBC Peel Hunt Ltd nor any of its affiliates, parent undertakings, subsidiary undertakings or subsidiaries of its parent undertakings or any of its respective directors, officers, employees or advisers or any other person accepts any responsibility whatsoever and makes no representation or warranty, express or implied, for or in respect of the contents of this announcement or as to the accuracy or completeness or fairness of the information or opinions contained in this announcement and, without prejudice to the generality of the foregoing, no responsibility or liability is accepted by any of them for any such information or opinions or for any errors or omissions. 

This announcement does not constitute an offer to sell or an invitation or solicitation to purchase or subscribe for any securities. The Placing and Open Offer will be made solely by the Prospectus which will contain the full terms and conditions of the Placing and Open Offer, including details of how the Placing and Open Offer may be accepted. Any acceptance or other response in relation to the Placing and Open Offer should be made only on the basis of the information contained in the Prospectus.

Any New Ordinary Shares issued or to be issued pursuant to the Prospectus have not been and will not be registered under the US Securities Act, or any relevant securities laws of any state of the United States. Subject to certain exceptions, such New Ordinary Shares may not be offered, sold or delivered in the United States or to or for the account or benefit of U.S. persons, as such terms are defined in Regulation S under the US Securities Act.

Definitions:

The following definitions apply throughout this announcement, unless the context requires otherwise:

"Admission"
the admission of the New Ordinary Shares (i) to the Official List and (ii) to trading on the London Stock Exchange's main market for listed securities becoming effective in accordance with, respectively LR 3.2.7G of the Listing Rules and paragraph 2.1 of the Admission and Disclosure Standards
 
 
"Admission and Disclosure Standards"
the requirements contained in the publication dated 7 September 2009
 
 
"Existing Ordinary Shares"
the 94,548,381 existing ordinary shares of 1 pence each in nominal value in the capital of the Company as at 3 December 2009
 
 
"Financial Services Authority"or "FSA"
the UK Financial Services Authority
 
 
"FSMA"
the Financial Services and Markets Act 2000 (as amended) and all regulations promulgated thereunder from time to time
 
 
"Listing Rules"
the listing rules made by the FSA in exercise of its function as competent authority pursuant to Part VI of FSMA
 
 
"London Stock Exchange"
London Stock Exchange plc
 
 
"New Ordinary Shares"
the 252,129,042 new Ordinary Shares of 1p each in nominal value in the capital of the Company proposed to be issued under the Placing and Open Offer
 
 
"Official List"
the Official List of the FSA
 
 
"Open Offer"
the conditional invitation to Qualifying Shareholders to apply for up to 252,129,042 New Ordinary Shares at the Offer Price on a pre-emptive basis
 
 
"Ordinary Share"
ordinary shares in the capital of the Company from time to time
 
 
"Overseas Shareholders"
Qualifying Shareholders who have registered addresses outside the United Kingdom
 
 
"Placing"
the conditional placing by KBC Peel Hunt of 172,090,285 New Ordinary Shares, subject to clawback pursuant to the Open Offer, on behalf of the Company on the terms and subject to the conditions contained in the Placing Agreement
 
 
"Placing Agreement"
the placing and open offer agreement dated 3 December 2009 between KBC Peel Hunt and the Company relating to the Placing and Open Offer
 
 
"Prospectus"
the prospectus in relation to the Placing and Open Offer dated 3 December 2009
 
 
"Qualifying Shareholders"
holders of Existing Ordinary Shares on the register of members of the Company on the Record Date (other than certain Overseas Shareholders)
 
 
"Record Date"
30 November 2009
 
 
"Shareholder"
a holder of Existing Ordinary Shares(s)
 
 
"US", "USA" or "United States"
 the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia
 
 
"US Securities Act"
the United States Securities Act of 1933, as amended

All references to "pounds", "pounds sterling", "Sterling", "£", "pence", "penny" and "p" are to the lawful currency of the United Kingdom.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEELFFKLBBFBX
Date   Source Headline
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc
11th Jun 202111:35 amRNSHolding(s) in Company
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.